Forecyte Bio
Latest round
- Series A
Last raised
- Dec 2021
Total raised
- Undisclosed
Investors
- 3
About Forecyte Bio
Based in Shanghai, China and founded in 2021, Forecyte Bio Limited is a company providing CDMO services in the field of cell and gene therapy. The company's CEO Ms. Yingke He worked in GSK for more than 20 years, and has experience in strategy design, project advancement, resource integration, and team building. The company's CTO Dr. Shuyuan Zhang has nearly 30 years of technical and managerial experience in gene and cell therapy process development and GMP manufacturing. The company's COO Dr. Yujian You has 14 years of business development and marketing experience in the life science field. The company's business includes plasmid production, viral vector production and cell therapy production. Its virus species include adeno-associated virus, adenovirus, lentivirus, lysozyme virus, retrovirus, etc. Its cellular products include CAR-T, TCR-T, CAR-NK, etc.
Who invested in Forecyte Bio
3 investors across 1 round
See all investors in Forecyte Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 23, 2021
Amount
Undisclosed
Investors
Questions about Forecyte Bio
Who invested in Forecyte Bio?
Forecyte Bio has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Forecyte Bio raised?
Forecyte Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Forecyte Bio last raise money?
Forecyte Bio's most recent round on record is a Series A, in Dec 2021.
What does Forecyte Bio do?
Based in Shanghai, China and founded in 2021, Forecyte Bio Limited is a company providing CDMO services in the field of cell and gene therapy.
Where is Forecyte Bio headquartered?
Forecyte Bio is headquartered in Shanghai, China.
Which VCs invest in companies like Forecyte Bio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Forecyte Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Forecyte Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.